Loading...
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl, H Hiller, L Howard, H Dunn, J Young, J Bowden, S McDermaid, M Waterhouse, A Wilson, Gregory Agrawal, R
Earl, H
Hiller, L
Howard, H
Dunn, J
Young, J
Bowden, S
McDermaid, M
Waterhouse, A
Wilson, Gregory
Agrawal, R
Citations
Altmetric:
Abstract
The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel.
Authors
Earl, H
Hiller, L
Howard, H
Dunn, J
Young, J
Bowden, S
McDermaid, M
Waterhouse, A
Wilson, Gregory
Agrawal, R
O'Reilly, S
Bowman, A
Ritchie, D
Goodman, A
Hickish, T
McAdam, K
Cameron, D
Dodwell, D
Rea, D
Caldas, C
Provenzano, E
Abraham, J
Canney, P
Crown, J
Kennedy, M
Coleman, R
Leonard, R
Carmichael, J
Wardley, Andrew M
Poole, C
Hiller, L
Howard, H
Dunn, J
Young, J
Bowden, S
McDermaid, M
Waterhouse, A
Wilson, Gregory
Agrawal, R
O'Reilly, S
Bowman, A
Ritchie, D
Goodman, A
Hickish, T
McAdam, K
Cameron, D
Dodwell, D
Rea, D
Caldas, C
Provenzano, E
Abraham, J
Canney, P
Crown, J
Kennedy, M
Coleman, R
Leonard, R
Carmichael, J
Wardley, Andrew M
Poole, C
Description
Date
2017-06
Publisher
Collections
Keywords
Type
Article
Citation
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. 2017, 18 (6):755-769 Lancet Oncol